After an impressive December rally, Bayer shares are also proving robust shortly before the turn of the year.
• Bayer shares have climbed by around 18 percent since the beginning of December and are currently trading steadily above the 35 euro mark
• There is optimism primarily because of a possible landmark decision by the US Supreme Court on the glyphosate trial
• Top analysts such as JPMorgan and Berenberg Bank have increased their price targets
From problem child to DAX leader
In the spring of 2025, Bayer shares were still considered one of the biggest negative factors on the German stock market. After the stock hit a long-term low of around 18.38 euros in April, a dynamic recovery began. In December alone, the stock rose massively and recently reached a new 2-year high of 37.14 euros. Despite minor profit-taking in the middle of the month, the upward trend remains intact, which currently makes Bayer one of the strongest performers in the DAX this year.
Double breakthrough: pharmaceutical pipeline and glyphosate
The new confidence in the market comes from two sources. On the one hand, Bayer provided positive impulses in the pharmaceutical sector: the drug Elinzanetant (menopausal symptoms) and new study data on the anticoagulant Asundexian give hope for future blockbuster sales. Experts see the strong pipeline as the key to getting Bayer back on track for growth after its long dry spell.
On the other hand, the US justice system creates fantasy. Political signals and the hope that the US Supreme Court will accept the glyphosate trial for review could significantly reduce the billion-dollar legal risks. Analysts at JPMorgan argue that containing the legal fallout would justify a massive jump in the stock’s valuation.
Bayer receives approval in Japan for finerenone for chronic heart failure
Bayer says it has received approval in Japan for its active ingredient finerenone for use in chronic heart failure. Japan’s Ministry of Health, Labor and Welfare (MHLW) has approved Finerenone or the brand Kerendia – a non-steroidal, selective mineralocorticoid receptor antagonist (nsMRA) – for the treatment of adult patients with chronic heart failure, the chemical and pharmaceutical company announced.
The approval is based on the positive results of the phase 3 study FINEARTS-HF, said Bayer. This offers a new treatment option for patients with chronic heart failure with a left ventricular ejection capacity (LVEF) of at least 40 percent.
Analyst upgrades fuel the price
The mood among the experts has brightened significantly. Berenberg Bank recently raised its price target from 30.40 euros to 41 euros. JPMorgan is even more optimistic: The US bank doubled its target from 25 to 50 euros and upgraded the paper to “overweight”. According to current TipRanks data, the stock is being monitored by a total of 13 analysts, with seven giving a clear buy recommendation (“Buy”) and six rating the stock as “Hold”. There are currently no sales recommendations.
Current price development of Bayer shares
At the start of the week, Bayer shares are no longer in a giving mood. After the paper left XETRA trading last Friday (December 19th) at 35.88 euros, today it is trading temporarily down 1.02 percent at 35.52 euros via XETRA. Nevertheless, the previous two-year high of EUR 37.14 remains within striking distance.
Editorial team finanzen.net / DOW JONES
Selected leverage products on Bayer
With knock-outs, speculative investors can participate disproportionately in price movements. Simply select the lever you want and we will show you suitable open-end products on Bayer
The leverage must be between 2 and 20
Advertising